Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC

Inclusion Criteria: Subjects may be entered in the study only if they meet all of the following criteria:

* Adult subjects aged ≥ 18 to 75 years (≥ 18 to 65 years for India) with histologically or cytologically confirmed advanced non-squamous NSCLC.
* Epidermal growth factor receptor (EGFR) negative or wild type mutations
* Stage IV (Unresectable recurrent disease or metastatic) NSCLC
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
* Evaluable disease status or measurable tumor
* Adequate hepatic, renal, and bone marrow function
* Subjects with pre-existing hypertension must be well controlled on a stable regimen of antihypertensive therapy. Have systolic blood pressure ≤ 140 and ≥ 90 mmHg, diastolic blood pressure ≤ 90 and ≥ 50 mmHg and heart rate ≥ 40 and ≤ 90 bpm at screening and admission.
* Ability to understand risks of participation in the study and willingness provide informed consent.

Exclusion Criteria: Subjects will not be entered in the study for any of the following reasons:

* Small cell lung cancer (SCLC) or combination of SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature
* Prior therapy with monoclonal antibodies or small molecule inhibitors against VEGF or VEGF receptors, including bevacizumab
* Prior therapy with carboplatin or paclitaxel
* Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or radiotherapy for locally-advanced NSCLC if completed \< 12 months prior to screening
* Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that in the opinion of the Investigator is likely to bleed
* Symptomatic brain metastasis
* Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix
* Any unresolved toxicity \> Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy)
* History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. Thrombotic or hemorrhagic event ≤ 6 months prior to screening
* History of hemoptysis greater than ½ teaspoon of bright red (fresh) blood in the past 4 weeks
* Subjects receiving long-term aspirin (\> 325 mg/day), or other non-steroidal anti-inflammatory agents, or other drugs known to inhibit platelet function, treatment with dipyridamole, ticlopidine, or clopidogrel
* Subjects receiving anticoagulants
* Subjects who plan to undergo surgery during the study period
* Subjects who have undergone a major surgery, or have had a significant traumatic injury within 4 weeks prior to randomization
* Subjects who have a significant non-healing wound, or bone fracture within 4 weeks prior to randomization
* Subjects with history of gastrointestinal perforation or fistula formation
* Subjects with known hypersensitivity to any of the ingredients of the investigational products, or mammalian cell-derived products
* Female subjects who are pregnant, breast-feeding, planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e., bilateral tubal ligation, total hysterectomy or \< 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period
* Male subject with a partner of childbearing potential who does not consent to the use of a reliable method of double contraception
* Subjects with uncontrolled hypertension
* Subjects with active infection assessed to be clinically significant by Investigator
* Known history of, or positive test result for human immunodeficiency virus (HIV), hepatitis C virus (test for hepatitis C virus antibody \[HCVAb\]) or hepatitis B virus (test for Hepatitis B surface Antigen \[HBsAg\])
* History of alcohol or substance abuse
* Prior treatment with any investigational drug within the 30 days prior to screening, or within 5 half-lives of the drug, whichever is longer
* Inability to comply with study requirements
* Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment.